fbpx
Connect with us

CBD CONDITIONS & TREATMENTS

Fibromyalgia and ECS Deficiency CBD Application

Published

on

As has become clear in recent years, CBD has a wide range of applications as a therapeutic treatment for many physiological ailments.

  • headaches,
  • diabetes,
  • PTSD,
  • anxiety,
  • hypertension,
  • cardiovascular disorders,
  • epileptic seizures
  • many more

We know that much of the evidence to support the health benefits of CBD remains in the class known as “anecdotal”, most major health revolutions start this way, and it takes more official research and data to get the FDA on board with the program. This may be developing as we speak.

But, in any case, we can’t make any claims that haven’t been supported by more official research. But we may be able to before long, so we will continue to outline how it works and report that anecdotal evidence under those conditions.

In this piece, we explore how it has potential application for those suffering from fibromyalgia and ECS deficiency.

Fibromyalgia

It has taken until just recently for fibromyalgia to be recognized as a serious and credible malady. In fact, very little is understood about this condition, with the exception that it can be weakening, and that no cure has been discovered as of yet.

That said, a huge number of individuals worldwide are currently starting to hope that CBD Oil may hold the key. As a reminder, we can’t make claims about CBD’s ability to truly treat this condition. But we can point to the facts:

  • fibers throughout the body send pain messages to the brain together
  • as of 35 years ago, no one really knew about this disease
  • it is now the most commonly diagnosed rheumatological illness, impacting about 10M US citizens
  • Women are more commonly diagnosed than men
  • Stress could be a contributing factor

Pain Sensitivity and Fibromyalgia

Individuals diagnosed with this condition as a rule additionally experience the ill effects of headaches, IBS, and Chronic Fatigue Syndrome as well. This had led to the theory that a very low pain tolerance is part of the disease.

This is interesting because we know, of course, that the body has a pain-directing system that reacts to various Cannabinoids found in plants – for example, Cannabis and Echinacea.

This system, the Endocannabinoid system, contains receptors that react to Cannabidiol or CBD. Receptors in the Endocannabinoid system are found in the immune system, the focal nervous system, and bone structure.

It has receptors that react to specific substances, and CBD connects with these receptors, and possibly gives help to upsetting symptoms. CBD can help alleviate pain by binding to microglial cells.

That can help to reduce cytokine levels and therefore diminish pain. Given that the issue here has to do with pain and inflammation, and we know that CBD is very effective as a treatment for pain and inflammation, it should be clear why we might choose to focus our analysis on the question of whether or not CBD may be a plausible tool in the battle against fibromyalgia.

Fibromyalgia, the ECS, and the Path Forward

To further put a fine point on the situation, we would like to circle back around now to the Endocannabinoid system and point out that the suffering in the case of fibromyalgia may be at least in part due to an insufficiency in the functioning of this key system.

Recall that CBD acts to help the ECS function better and make more effective use of its own endocannabinoids.

The ECS is highly tied into many physiological systems and its dysfunction can lead to, among other things, intolerable generalized pain and inflammation. Now and again when this system does not work as it should, it is called Clinical Endocannabinoid Deficiency.

Fibromyalgia, in many ways, matches this type of scenario, which is cause to deepen the research process and establish the extent to which this condition may be a prime case of something very well-targeted by a strong regimen of CBD exposure.

CBD CONDITIONS & TREATMENTS

CannTrust Holdings Inc (NYSE:CTST) Penetrates Into The United States After Investing $20 Million

Published

on

CannTrust Holdings Inc (NYSE:CTST), a Canadian company that produces and sells medical and recreational marijuana has announced the expansion of its business into the United States.

The Canadian firm revealed that it signed a Letter of Intent through which it will start working with Elk Grove Farming Company, LLC to access more than 3,000 hemp production acres in California. The two companies struck a joint partnership that will allow CannTrust to secure a footing in the California market which is one of the biggest cannabis markets in the U.S.

“This agreement represents another bold move for CannTrust. Our U.S. operation is expected to deliver a significant increase in low-cost production capacity,” stated CannTrust CEO Peter Aceto.

CannTrust is financially ready to tap into the U.S market

The CannTrust CEO also noted that the company will take advantage of its experience in the formulation of standardized CBD products as part of its strategy to enter the U.S market. Mr. Aceto also revealed that his company’s successful equity offering provided enough financial muscle to fuel its ambitious expansion plans.

CannTrust aims to be among the leading and trusted suppliers of high-quality, standardized CBD formulations derived from hemp. The company believes that there will be an increasing demand for high-grade CBD formulations from international retailers. It therefore makes sense to invest in processes that will add value to the end product such as genetic studies and expert growing practices to achieve the highest safety and quality standards.

Elk Grove and CannTrust will each have 50% ownership in their joint operations. Elk Grove is an ideal partner for the endeavor because it has years of farming experience in a variety of products. Its focus includes products designed for crop protection, supply, and input. Its operations are distributed across California, which means that the groundwork has already been laid for the partnership. It will thus be easier for the CannTrust to penetrate into the California market.

Elk Grove executive Morgan Houchin stated that his company was excited about the partnership with CannTrust. He added that his firm’s experience in farming operations will be a great combination with CannTrust’s experience in creating class-leading formulations.

Continue Reading

CBD CONDITIONS & TREATMENTS

Rocky Mountain High Brands Inc (OTCMKTS:RMHB) Strikes Broker Deal With Carlin Group

Published

on

Lifestyle brand management firm Rocky Mountain High Brands Inc (OTCMKTS:RMHB) announced on Wednesday that it secured a broker deal with Carlin Group for its products in the retail space.

The broker agreement will allow Carlin to represent RMHB’s CBD-infused drinks through the HEMPd brand. It will also represent beverages infused with Hempseed extract under RMHB brands. The deal will also cover CBD-infused wellness products such as lotions, water-soluble solutions, capsules, gummies and tinctures as part of the HEMPd brand. Spirit Water will also be covered under the agreement.

The RMHB-Carlin broker deal covers multiple states. They include Missouri, Nebraska, Texas, South Dakota, North Dakota, Minnesota, Wisconsin, Illinois, Pennsylvania, Tennessee, Kentucky, Ohio, Indiana, and Michigan.

“We are very excited about the opportunity to have our entire product line represented by Carlin Group,” stated RMHB CEO Michael Welch.

The Carlin broker deal will boost RMHB’s exposure

Welch noted that the broker deal will strategically allow RMHB to leverage optimal exposure to mass marketers, grocery store chains, convenient stores, major retailers and other types of outlets. The company would not have managed to reach such a wide range of outlets cost-effectively without a broker deal.

The RMHB CEO also added that his company and Carlin will maintain a close collaboration so that they can facilitate retail availability of RMHB products. Welch also revealed that RMHB reviewed numerous other retail introduction options. This was before settling on Carlin which the company believes is the best-suited brand to rapidly get its products onto retail shelves.

Carlin Group’s Managing Director Albert Vergilio noted in a statement that his company was excited to host RMHB and the CBD-based products that are part of its HEMPd brand in Carlin’s new CBD division. He also added that it is part of investing in the future of CBD considering the fast-tracked popularity of CBD products, and the regulations that govern them.

Carlin’s sales team will undergo some training to get them acquainted with RMBH’s products. The sales team will then hold meetings with corporate customers as part of the retail rollout of the products. Sales that will be part of the broker deal are expected to kick off in Q3.

Continue Reading

CBD CONDITIONS & TREATMENTS

Wildflower Brands Inc (OTCMKTS:WLDFF) Establishes Footprint Across The US With PO For Hemp CBD Products From Dillard’s Department Stores And Eyes Markets In Texas And Florida

Published

on

Wildflower Brands Inc (OTCMKTS:WLDFF) has announced establishing a nationwide presence with a PO from Dillard’s Department store. The company has fulfilled the PO received from Dillard.

Hemp CBD products in 292 locations

Dillard’s department store will showcase the premium hemp CBD products of Wildflower in its 292 locations across the US. With its best practices and transparency, Wildflower is eyeing the key markets in Texas and Florida. The company will educate the customers in these regions about salable products. Wildflower has received subsequent orders from Dillard’s and is fulfilling the requirements.

Chief Executive Officer of Wildflower, William Maclean said the supply of CBD infused products to Dillard’s Department stores doubles the existing retail locations in the nation. The company aims to capitalize on its brand to become a household name. It will improve loyalty building because of the reputation and respect of Dillard’s as a retailer. Wildflower aims to provide health and wellness benefits of its CBD infused products to the customers in the US through Dillard’s.

Signs a deal with Highmark Interactive

Wildflower has signed a deal to use EQ – Brain Tracking, mobile software of Highmark Interactive, in the clinical research to study the functional neurological and cognitive effects of CBD. The company aims to get meaningful results and data that help to understand the functional and cognitive neurological properties of the cannabinoids.

William said the company would collect testimonials from the customers on its products that provide the health and wellness needs using plant-based solutions. The company will strive to improve the products, and the research helps it to reach that goal and growth with continued investments.

Acquires City Cannabis Corp

Wildflower has signed an LOI on April 3, 2019, to take over City Cannabis Corp. The company will issue its 60 million common shares for the takeover. The companies will complete the acquisition on receiving advice from corporate, tax, and securities law departments.

The cannabis retailer City Cannabis holds two licenses in the City of Vancouver to market cannabis. It is generating profits through operating dispensaries in Vancouver. The acquisition helps Wildflower to expand retail footprint using the expertise of City Cannabis.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories